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Abstract Dystroglycan is a component of the dystrophin gly-
coprotein complex that is cleaved into two polypeptides by an
unidenti¢ed protease. To determine the role of post-translational
processing on dystroglycan synthesis and tra⁄cking we ex-
pressed the dystroglycan precursor and mutants thereof in a
heterologous system. A point mutant in the processing site,
S655A, prevented proteolytic cleavage but had no e¡ect upon
the surface localisation of dystroglycan. Mutation of two
N-linked glycosylation sites that £ank the cleavage site inhibited
proteolytic processing of the precursor. Furthermore, chemical
inhibition of N- and O-linked glycosylation interfered with the
processing of the precursor and reduced the levels of dystrogly-
can at the cell surface. Dystroglycan processing was also inhib-
ited by the proteasome inhibitor lactacystin. N-linked glycosyl-
ation is a prerequisite for e⁄cient proteolytic processing and
cleavage and glycosylation are dispensable for cell surface tar-
geting of dystroglycan.
* 2003 Published by Elsevier B.V. on behalf of the Federation
of European Biochemical Societies.
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1. Introduction
Transport of proteins to the cell surface is a complex pro-
cess involving glycosylation, folding and sorting. These pro-
cesses are initiated in the endoplasmic reticulum (ER) and
continue in the Golgi apparatus as the protein proceeds along
the secretory pathway [1]. An elaborate system for protein
quality control exists such that misfolded proteins are re-
moved from the ER and degraded in the cytoplasm by the
proteasome [2]. Defects in the post-translational processing of
dystroglycan, a component of the dystrophin glycoprotein
complex (DGC), are a common feature of some congenital
muscular dystrophies (CMDs) [3,4]. Dystroglycan is processed
by an as yet unidenti¢ed protease into two proteins, the trans-
membrane dystrophin-binding protein L-dystroglycan and the
extracellular matrix receptor K-dystroglycan [5]. In addition to
the proteolytic processing both K- and L-dystroglycan are gly-
cosylated. K-Dystroglycan is glycosylated in a tissue-speci¢c
manner to produce a number of distinct glycoforms [5]. Gly-
cosylation of dystroglycan is required for binding to a number
of extracellular proteins such as laminin [6] and agrin [7,8] and
has also been implicated in viral [9] and bacterial adherence
[10].
Several forms of CMD are associated with secondary alter-
ations in dystroglycan processing (for recent review see [3]).
These diseases include, Fukuyama congenital muscular dys-
trophy (FCMD), Muscle^eye^brain (MEB) disease, congenital
muscular dystrophy type 1C (MDC1C) and Walker^Warburg
syndrome (WWS) [11^15]. Furthermore, the myodystrophy
(myd) mouse mutant also has secondary abnormalities in dys-
troglycan processing [16]. Each of these disorders is caused by
mutation in an actual or putative glycosyltransferase. Muta-
tions in protein O-mannosyltransferase 1 (POMT1) that cause
WWS are predicted to block the ¢rst step in O-mannosyla-
tion. POMGnT1 is mutated in MEB and encodes a glycosyl-
transferase that catalyses the addition of N-acetylglucosamine
to a peptide linked mannose residue [12]. Thus POMT1 and
POMGnT1 are thought to catalyse sequential steps in the
synthesis of O-linked glycans on K-dystroglycan. Patients
with FCMD and MDC1C have mutations in two homologous
proteins, fukutin and FKRP, that are predicted to be phos-
phoryl ligand transferases and possibly glycosyltransferases
[13,17]. Consistent with a role in protein processing, these
putative enzymes are found in the Golgi apparatus [18].
Dystroglycan processing and maturation poses a number of
challenges to the cell. Dystroglycan is a heterodimeric receptor
that is cleaved into two polypeptides which are heavily glyco-
sylated and self-associate at the plasma membrane. Given that
secondary defects in dystroglycan processing cause di¡erent
forms of CMD we determined whether post-translational pro-
cessing was a prerequisite for dystroglycan synthesis and traf-
¢cking in vitro.
2. Materials and methods
2.1. Cloning and site-directed mutagenesis
The construct encoding chick dystroglycan cDNA (ChDG, EMBL
accession number AJ584830) has been described previously [18]. The
programs NetOGlyc 2.0 (http://www.cbs.dtu.dk/services/NetOGlyc/)
and NetNGlyc 1.0 Prediction (http://www.cbs.dtu.dk/services/NetN-
Glyc/) were used to predict potential O- and N-linked glycosylation
sites [19]. Pfu Turbo DNA polymerase (Stratagene) was used to create
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mutations in ChDG as described previously [18]. All constructs were
sequence-veri¢ed. The primers used are shown below with mutated
nucleotides underlined: DG655f : 5P-G GAC ATC GCC AAG GGC
GCG ATC GTG GTG GAA TGG; DG655r : 5P-CCA TTC CAC
CAC GAT CGC GCC CTT GGC GAT GTC C; DG556f : 5P-TCG
TGG GTC CAG TTC GCC AGC ACC AGC CAG C; DG556r : 5P-
G CTG GCT GGT GCT GGC GAA CTG GAC CCA CGA;
DG642f : 5P-G TTC GGC GAT AGG GCC AGC AGC ACC ATC
AC; DG642r : 5P-GT GAT GGT GCT GCT GGC CCT ATC GCC
GAA C; DG662f : 5P-GTG GTG GAA TGG ACC GCC AAC ACC
CTG CCC; DG662r : 5P-GGG CAG GGT GTT GGC GGT CCA
TTC CAC CAC; DG730f : 5P-GAC GGC AGG GTG ATC GCG
GAG GCG ACG CC; DG730r : 5P-GG CGT CGC CTC CGC
GAT CAC CCT GCC GTC; DG733f : 5P-GTG ATC TCG GAG
GCG GCG CCG ACG CTG G; DG733r : 5P-C CAG CGT CGG
CGC CGC CTC CGA GAT CAC; DG735f : 5P-GAG GCG ACG
CCG GCG CTG GCG GCT GGG AAG; DG735r : 5P-CTT CCC
AGC CGC CAG CGC CGG CGT CGC CTC.
2.2. Tissue culture, transfection and drug treatment
CHO, HEK and COS-7 cells were maintained and transfected as
described previously [18]. Cells were treated with glycosylation inhib-
itors (10 Wg ml31 tunicamycin, TM (Sigma); 4 mM benzyl-GalNAc
(Sigma) and glucosidase inhibitors (2 mM 1-deoxynojirimycin (Sig-
ma); 50 Wg ml31 castanospermine (Sigma)). Lactacystin (Sigma) and
leupeptin (Sigma) were added to the cells 24 h after transfection at
¢nal concentrations of 10, 50 and 20 WM, respectively. Cells lysates
were prepared from 5U105 cells 48 h after transfection and approx-
imately 50 Wg was used for Western blot analysis as described previ-
ously [20].
2.3. Antibodies and immunocytochemistry
The following primary antibodies were used in this study: 43DAG
8D5 (Novocastra), mouse monoclonal speci¢c to L-dystroglycan that
detects expressed ChDG and endogenous L-dystroglycan in CHO,
COS-7 and HEK cells. Anti-K/L-dystroglycan is a rabbit polyclonal
antibody raised against a bacterially express fusion protein spanning
the processing site of chick dystroglycan [18]. This antibody detects
chick K- and L-dystroglycan but does not cross-react with endogenous
dystroglycan in CHO, COS-7 and HEK cells. The K-dystroglycan-
speci¢c sheep antibody has been described previously [21]. Cells
were processed for immunocytochemistry as described previously [18].
2.4. Flow cytometry
HEK cells stably expressing the ChDG cDNA were grown in cul-
ture for 24 h. The cells were then treated with inhibitors as mentioned
above and grown for a further 24 h. Cells were detached from the
tissue culture dish with Versene (Gibco, Life Technologies) and cen-
trifuged at 500Ug for 3 min. Cells were incubated with the K/L poly-
clonal antibody diluted 1:100 with phosphate-bu¡ered saline (PBS)/
1% bovine serum albumin (BSA) for 45 min at room temperature.
The cells were washed with PBS/1% BSA, centrifuged as above, and
incubated at room temperature for 45 min with Alexa 488-conjugated
anti-rabbit IgG (Molecular Probes). Cells were washed again and re-
suspended in 300 Wl PBS/1% (w/v) BSA. The £uorescence on the cell
surface was assayed using a FACScan Flow Cytometer (Becton Dick-
inson).
2.5. Immunoblotting
Forty-eight hours after transfection cells were lysed with sodium
dodecyl sulfate^polyacrylamide gel electrophoresis (SDS^PAGE) sam-
ple bu¡er containing 5% (v/v) 2-mercaptoethanol. Proteins were sep-
arated by SDS^PAGE on either 4^15% gradient gels (BioRad) or 10%
gels, transferred to a nitrocellulose membrane (Schleicher and Schuell)
and probed with antibodies against dystroglycan as described previ-
ously [18]. Proteins were visualised using enhanced chemiluminescence
(Pierce).
2.6. Enzymatic deglycosylation
Proteins were extracted from transfected cells in PBS (Sigma) con-
taining 1% (v/v) Triton X-100. Twenty Wg of protein extract was
boiled for 10 min in denaturing bu¡er (0.5% (w/v) SDS, 1% (v/v)
2-mercaptoethanol) prior to enzymatic deglycosylation. Treatment
with PNGase F (Sigma) and Endo H (Sigma) were performed accord-
ing to the manufacturer’s recommendations. Samples were used for
immunoblotting as described above.
3. Results
3.1. E¡ect of proteolytic processing on dystroglycan
Dystroglycan is processed into two polypeptides in vivo and
in vitro. Sequence analysis around the processing site for the
dystroglycan precursor revealed remarkable sequence similar-
ity to the processing sites for several proteins that contain
SEA-modules (Fig. 1A). In common with dystroglycan these
proteins are also decorated with O-linked glycans and remain
associated with their respective cleavage partner at the cell
surface (see [22] for review). To determine whether proteolytic
processing was a prerequisite for cell surface localisation, the
cleavage site of ChDG was altered from serine to alanine
(S655A) by site-directed mutagenesis. This amino acid is in-
variant in all SEA-module-containing proteins that have an
internal proteolytic cleavage site (Fig. 1A). The mutant dys-
troglycan was synthesised at normal levels and glycosylated,
however the mutation completely blocked cleavage into the
K- and L-subunits (Fig. 1B). CHO cells transfected with the
S655A mutant construct expressed K-dystroglycan on the cell
surface and were indistinguishable from cells expressing wild-
type dystroglycan precursor (Fig. 1C). Punctate cell surface
immunoreactivity was seen in all cell types (data not shown).
These data show that proteolytic processing is not necessary
for membrane localisation of K-dystroglycan.
3.2. E¡ect of glycosylation inhibitors on dystroglycan
tra⁄cking and processing
Expression of ChDG in CHO cells produces dystroglycan
that is processed into three major proteins, L-dystroglycan (43
kDa), K-dystroglycan (160 kDa) and a 90 kDa immature form
of K-dystroglycan [18]. In order to determine the N-linked
glycosylation pro¢le of dystroglycan, protein extracts were
prepared from ChDG-transfected CHO cells, and incubated
with PNGase F (cleaves N-linked glycans regardless of com-
plexity) and Endo H (cleaves high mannose N-glycans). The
molecular weight of L-dystroglycan was decreased in both
cases (Fig. 2A), and the polypeptide generated by PNGase
F was smaller than the Endo H product indicating that at
least two N-linked sites on L-dystroglycan had been glycosy-
lated. In chick dystroglycan these sites are located at residues
N662 and N705, however only N662 is conserved across dif-
ferent species (see Fig. 4A). The relative molecular mass of
K-dystroglycan was also decreased by PNGase F digestion
indicating the presence of N-linked glycans (Fig. 2A). Endo
H had no apparent e¡ect on the relative molecular mass of
K-dystroglycan (Fig. 2A).
To determine the e¡ects of glycosylation on dystroglycan
processing, CHO cells were transfected with the ChDG cDNA
followed by treatment with inhibitors of glycosylation.
Cells were treated with tunicamycin, which inhibits en bloc
N-glycosylation, benzyl-GalNAc, which inhibits mucin-like
O-linked glycosylation, deoxynojirimycin and castanosper-
mine, which are inhibitors of ER glucosidase I and II. Tuni-
camycin treatment resulted in the selective loss of L-dystrogly-
can and a reduction in the level of K-dystroglycan (Fig. 2B).
The data were con¢rmed with the L-dystroglycan-speci¢c anti-
body 43DAG 8D5 that showed that endogenous and heterol-
ogous L-dystroglycan was lost following tunicamycin treat-
ment (data not shown). A slight reduction in the size of
K-dystroglycan was also observed following tunicamycin
treatment con¢rming the presence of N-linked glycans. In
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cells treated with benzyl-GalNAc, there was an approximate
2 kDa decrease in the relative molecular weight of L-dystro-
glycan indicating the presence of O-linked glycans and show-
ing that the drug was active in CHO cells (Fig. 2B). This
decrease was observed consistently over a range of benzyl-
GalNAc concentrations (data not shown). Benzyl-GalNAc
treatment also reduced the levels of K-dystroglycan but sur-
prisingly had no apparent e¡ect upon the relative molecular
mass of K-dystroglycan (Fig. 2B). Deoxynojirimycin and cas-
tanospermine increased the abundance of the 160 and 90 kDa
bands (Fig. 2B), and castanospermine treatment also caused a
slight increase in the relative molecular mass of L-dystrogly-
can, presumably by inhibiting the action of ER glucosidases.
Similar results were obtained in HEK and COS cells (data not
shown).
Flow cytometry and immunocytochemistry was used to de-
termine the steady state levels of K-dystroglycan at the cell
      
      
    
   
    
 
Fig. 1. The e¡ects of proteolytic processing on dystroglycan tra⁄ck-
ing. A: Sequence alignment of the processing site of dystroglycan
precursor with similar regions in a subset of SEA-module containing
proteins. GgDG, chicken dystroglycan; HsDG, human dystrogly-
can; SsEntk, pig enterokinase [34]; GgSPACR, chicken sialoprotein
associated with cones and rods [35] ; HsMuc1, human mucin-1;
RnIgHepta, rat Ig-Hepta [36]. The position of the cleavage site be-
tween the conserved glycine and serine residue is indicated with an
arrow. B: Extracts prepared from transfected CHO cells were blot-
ted with antibodies against K-/L-dystroglycan (K/L) and L-dystrogly-
can (43DAG 8D5). The S655A mutant protein was uncleaved (as-
terisk) and detectable with both antibodies. The 43DAG 8D5
antibody also detected endogenous L-dystroglycan (Le). The 90 kDa
protein in cells expressing ChDG corresponds to the immature form
of K-dystroglycan. C: K-Dystroglycan was detected on the surface
of CHO cells transfected with both wild-type (ChDG) and mutant
(S655A) constructs. In control experiments no labelling was detected
with 43DAG 8D5 that detects an intracellular epitope, indicating
that paraformaldehyde ¢xation had not rendered the cells permeable
to antibodies.
Fig. 2. Glycosylation pro¢le and proteolytic processing of chick dys-
troglycan. A: Western blot of digested protein extracts derived from
ChDG-transfected CHO cells, probed with the K-/L-dystroglycan
antibody (K/L). PNGaseF and EndoH treatment reduced the size of
L-dystroglycan, con¢rming the presence of N-glycans. PNGaseF
also reduced the size of K-dystroglycan, demonstrating the presence
of N-linked glycans. Proteins were resolved on 4^15% gradient gels.
B: CHO cells were transfected with ChDG followed by incubation
with inhibitors of glycosylation. Western blots of cell extracts
were probed with an antibody against K-/L-dystroglycan (K/L). In
cells treated with tunicamycin (TM) the 160 kDa K-dystroglycan
band was deglycosylated with a reduced level of expression whereas
L-dystroglycan was completely absent. The molecular weight of
L-dystroglycan was reduced in benzyl-GalNAc (BGN)-treated cells.
Deoxynorjirimycin (DNJ) and castanospermine (CAS) increased gly-
cosylation of the 160 and 90 kDa products, and CAS increased the
molecular weight of L-dystroglycan.
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surface following treatment with the di¡erent glycosylation
inhibitors. For these experiments we used a stable HEK cell
line that expresses ChDG and transiently transfected CHO
and COS-7 cells. Living, non-permeabilised cells were labelled
with the sheep anti-K-dystroglycan antibody that detects
extracellular epitopes on K-dystroglycan. In all cases surface
labelling of dystroglycan was observed irrespective of the drug
used. However, cells treated with tunicamycin and benzyl-
GalNAc showed a reduction in £uorescence intensity indicat-
ing that less dystroglycan was present on the cell surface (Fig.
3). Similar results were obtained with transiently transfected
CHO and COS-7 cells (data not shown). Castanospermine
and deoxynojirimycin treatment caused a small increase in
£uorescence intensity compared to the untreated control
(Fig. 3) consistent with the increase in K-dystroglycan seen
on Western blots (Fig. 2B). In control experiments no label-
ling was detected with antibodies raised against the intracel-
lular epitopes showing that dystroglycan at the cell surface
had the correct orientation and that only surface labelling
was being observed.
Fig. 3. Inhibition of N- and O-linked glycosylation does not prevent tra⁄cking of K-dystroglycan to the cell surface. Flow cytometry was used
to measure surface expression of K-dystroglycan on HEK cells stably expressing ChDG using an antibody against K-/L-dystroglycan. The pri-
mary antibody incubation step was omitted in controls. Tunicamycin and benzyl-GalNAc reduced the surface expression of dystroglycan.
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Fig. 4. Mutagenesis of putative glycosylation sites in ChDG. A: Sequence alignment £anking the processing site (arrow) of dystroglycan show-
ing putative N- and O-linked glycosylation sites. Gg, Gallus gallus ; Hs, Homo sapiens ; Bt, Bos taurus ; Mm, Mus musculus ; Oc, Oryctolagus cu-
niculus ; Xl, Xenopus laevis ; Dr, Danio rerio. CHO cells were transfected with wild-type dystroglycan (ChDG) and mutations thereof, including
the processing site mutant S655A. Cell lysates were analysed by SDS^PAGE and Western blotting with antibodies against K-/L-dystroglycan
(K/L upper panel, B) and L-dystroglycan (43DAG 8D5 lower panel, B). Mutated amino acids, N556, S655, N662 and T735 altered the relative
molecular mass of dystroglycan and/or the stoichiometry of the two proteins. By contrast, the mutations N642A, S730A and T733A did not al-
ter the molecular weight of dystroglycan. Note that the mutants S655A and N662A also reduced the steady state levels of endogenous L-dystro-
glycan (Le). L-Dystroglycan produced by the T735 mutant co-migrates with endogenous L-dystroglycan. To determine whether the proteins
were shed into the culture media, WGA-bound proteins from culture supernatants were probed with the K/L polyclonal antibody (C). Proteins
with increased relative molecular mass were seen in cells expressing the mutants S655A and N662A. The identity of the proteins detected by
each antibody is shown.
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3.3. E¡ect of single glycosylation site mutants on dystroglycan
processing
We have demonstrated a functional requirement for both
N- and O-linked glycosylation for e⁄cient processing and
tra⁄cking of dystroglycan. To speci¢cally determine the mo-
lecular mechanism that controls glycosylation-dependent dys-
troglycan tra⁄cking, putative glycosylation sites were altered
by site-directed mutagenesis. The residues were chosen based
upon their proximity to the proteolytic processing site, their
prediction to be glycosylated and their cross-species conserva-
tion (Fig. 4A). These included two sites on K-dystroglycan
(N556A and N642A) nearest to the cleavage site, and four
sites on L-dystroglycan (N662A, S730A, T733A and T735A)
on the extracellular side of the transmembrane region. The
mutants were transfected into CHO cells to determine which
sites were occupied by glycans and whether glycosylation at
these sites was a requirement for proteolytic processing of the
precursor. Mutation of T735A decreased the relative molec-
ular mass of L-dystroglycan by approximately 2 kDa but did
not alter the processing or stochiometry of K- and L-dystro-
glycan (Fig. 4B). The downward shift in relative molecular
mass is identical to that seen with benzyl-GalNAc (Fig. 2B)
suggesting that there is an O-linked glycan on L-dystroglycan
at T735. No di¡erences in the relative molecular mass of
L-dystroglycan and the processing of the dystroglycan precur-
sor were apparent in the mutants S730A and T733A (Fig. 4B).
The mutant N662A behaved similar to the processing site
mutant S655A (Fig. 4B). The N662A mutation completely
abolished cleavage of the precursor protein resulting in lower
levels of an uncleaved high molecular weight dystroglycan
that was also detected with an antibody speci¢c to L-dystro-
glycan (Fig. 4B). Interestingly synthesis of the mutants N662A
and S655A interferes with the processing of endogenous dys-
troglycan such that lower levels of the protein are found in
cell extracts from the uncleaved mutant compared to those in
wild-type extracts or extracts prepared from the normally pro-
cessed mutants (Fig. 4B).
Mutation of N556A in K-dystroglycan clearly reduced the
levels of K-dystroglycan (Fig. 4B). This mutation is also asso-
ciated with defective processing of the precursor because a
high molecular weight protein is detected in the lysate with
43DAG 8D5 (Fig. 4B). By contrast, the mutation N556A in
K-dystroglycan had no apparent e¡ect on the processing of
endogenous dystroglycan. Similarly, mutation of N642A had
no obvious e¡ect on dystroglycan processing or synthesis (Fig.
4B).
Several reports have shown that dystroglycan can be se-
creted from some cell lines [23^25]. To determine the e¡ects
of dystroglycan post-translational processing on this process,
we tested two potential mechanisms for secretion or shedding
of dystroglycan into the culture media: (1) Shedding is caused
by dissociation of K- and L-dystroglycan at the membrane.
(2) Shedding is due to limited proteolysis of K-dystroglycan.
To distinguish between these possibilities we assayed WGA
(wheat germ agglutinin) puri¢ed tissue culture supernatants
from cells transfected with wild-type chick dystroglycan and
the repertoire of mutants used in this study. Dystroglycan is
detected in all the supernatants including those from the un-
cleavable mutants S655A and N662A. Anomalously high mo-
lecular weight dystroglycan (s 180 kDa) was recovered from
the supernatants of cell expressing the mutants S655A and
N662A (Fig. 4C). The recovered protein is only detected by
antibodies raised against K-dystroglycan and not with 43DAG
8D5, which detects an intracellular epitope on L-dystroglycan
(data not shown). These data therefore suggest that proteol-
ysis is the cause of K-dystroglycan shedding into the super-
natant.
3.4. E¡ect of the proteasome inhibitor lactacystin on
dystroglycan synthesis
Using site-directed mutagenesis and drug inhibition we have
generated complementary data to show that N-linked glyco-
sylation is a prerequisite for dystroglycan processing. The as-
paragine mutations that inhibit dystroglycan cleavage are as-
sociated with reduced synthesis of the precursor suggesting
that the lack of N-glycosylation may cause protein misfolding
and concomitant degradation by the proteasome. In addition,
tunicamycin treatment reduces the level of K-dystroglycan and
causes the selective loss of L-dystroglycan (Fig. 2B). To deter-
mine the fate of tunicamycin-treated dystroglycan, cells were
transfected with ChDG and incubated for 24 h with tunica-
mycin alone and in combination with the proteasome inhib-
itor, lactacystin or with the inhibitor of lysosomal proteases,
leupeptin. COS-7 cells were used because the combination of
tunicamycin and lactacystin was toxic to CHO cells. Tunica-
mycin treatment resulted in the degradation of L-dystroglycan
accompanied by a reduction in the amount of K-dystroglycan
(Fig. 5A), as was the case in CHO cells (Fig. 2B). In cells
treated with tunicamycin and lactacystin a 160 kDa band
was detected using the L-dystroglycan-speci¢c antibody (Fig.
5A). This suggests that tunicamycin treatment partially inhib-
its processing of dystroglycan and that the unprocessed and
hypo-glycosylated dystroglycan is normally degraded via the
proteasome pathway. Processed L-dystroglycan was not de-
tected even with the addition of lactacystin or leupeptin
(Fig. 5A), probably due to the requirement for N-linked gly-
cosylation for e⁄cient proteolytic processing (Fig. 4B).
Similar experiments were conducted on the N662A mutant
(Fig. 5B). Addition of lactacystin increased the abundance of
a lower molecular weight protein that was detected by both
the K/L polyclonal and 43DAG 8D5 antibodies (Fig. 5B). In
cells treated with lactacystin or lactacystin and leupeptin no
endogenous L-dystroglycan could be detected suggesting that
the proteasome inhibitor also interferes with the processing of
the dystroglycan precursor (Fig. 5B). Accordingly, 43DAG
8D5 detects a doublet in cells treated with lactacystin that
corresponds to the uncleaved endogenous and chick dystro-
glycan proteins. Addition of leupeptin to cells expressing the
N662A mutant failed to increase the levels of dystroglycan in
the lysate suggesting that the lysosome does not play a major
role in the degradation of the transfected mutants (Fig. 5B).
To determine whether lactacystin had a direct e¡ect on dys-
troglycan processing, cells were transfected with wild-type
ChDG and treated with the drug. Lactacystin treatment re-
sulted in a dramatic reduction in the amount of L-dystrogly-
can and an increase in the levels of the 90 kDa immature form
of K-dystroglycan (Fig. 5C). 43DAG 8D5 detected signi¢cant
amounts of uncleaved dystroglycan in cells treated with lacta-
cystin and also a clear reduction in the levels of processed
endogenous and chick L-dystroglycan (Fig. 5C). Conversely,
leupeptin had no apparent e¡ect upon the steady state levels
of dystroglycan. These data show that lactacystin blocks mat-
uration of the dystroglycan precursor by inhibiting cleavage
and possibly glycosylation.
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4. Discussion
We have used an in vitro expression system to study the
role of glycosylation and proteolytic processing on the syn-
thesis and tra⁄cking of dystroglycan. In this study we have
presented complementary evidence showing that glycosylation
and proteolytic processing of dystroglycan are dispensable for
cell surface expression. We also show that N-linked glycosyl-
ation is important for proteolytic processing of dystroglycan.
To determine whether proteolytic processing was a prereq-
uisite for cell surface expression a mutant dystroglycan that
could not be processed was generated. This construct was
e¡ectively targeted to the surface of CHO cells despite the
lack of processing. What then is the signi¢cance of the cleav-
age and re-association of the dystroglycan subunits? We have
shown that the cleavage site, S655, is part of a conserved
sequence found in SEA-modules that were ¢rst identi¢ed in
a sperm protein, enterokinase and agrin (Fig. 1A) [22,26].
Importantly, this site is only conserved in SEA-domain pro-
teins that are proteolytically processed. The SEA-module is
found in a number of highly O-linked glycosylated membrane
proteins including mucin-1. Wreschner et al., have proposed a
mechanism whereby SEA-mediated cleavage generates a re-
ceptor^ligand partnership from the same protein for the pur-
Fig. 5. The e¡ect of lactacystin (LC) and leupeptin (LP) on dystroglycan processing. COS-7 cell extracts were prepared from cells transfected
with ChDG and treated with tunicamycin (TM) and TM and LC (A). TM treatment causes the loss of L-dystroglycan and a reduction in the
level of K-dystroglycan. Addition of LC increases the level of K-dystroglycan and stabilises the unprocessed precursor that can be detected with
43DAG 8D5. The e¡ect of LC and LP on the steady state levels of the N662A mutant was assessed under the same conditions (B). LC in-
creases the abundance of precursor protein that is detected with the K/L polyclonal antibody and as a doublet with 43DAG 8D5. LC treatment
also blocked processing of endogenous dystroglycan as resulting in a high molecular weight protein detected by 43DAG 8D5 and no endoge-
nous L-dystroglycan (Le). LP treatment had no apparent e¡ect upon the mutant in the presence and absence of LC. LC also inhibits processing
of wild-type ChDG (C) whilst LP had no apparent e¡ect. The identity of the proteins detected by each antibody is shown.
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pose of regulating signal transduction [22]. It is therefore pos-
sible that the binding of K-dystroglycan to one of its extra-
cellular ligands elicits a signal through the SEA-module to
L-dystroglycan. Recently Jayasinha et al. have shown that
overexpression of an uncleavable dystroglycan mutant (mouse
S654A) in transgenic mice causes muscular dystrophy associ-
ated with defective dystroglycan processing and glycosylation
[27,28]. These data suggest that proteolytic cleavage is essen-
tial for faithful glycosylation and that the uncleavable mutant
has the ability to inhibit the synthesis and glycosylation of
endogenous dystroglycan [27,28]. Our ¢ndings described in
this paper are in broad agreement with the behaviour of the
S654A mutant in transgenic mice.
The glycans on K-dystroglycan are essential for binding to a
number of extracellular matrix proteins including laminin [29].
Whilst glycosylation of K-dystroglycan is important for pro-
tein:protein interactions it is unclear whether the glycans are
involved in processing and tra⁄cking of the precursor protein.
Furthermore, the role of glycosylation in L-dystroglycan is not
understood. Using chemical inhibitors of glycosylation we
have shown that tunicamycin and benzyl-GalNAc reduce
but do not prevent dystroglycan tra⁄cking to the cell surface.
These data are in contrast to a study showing that tunicamy-
cin inhibited tra⁄cking of dystroglycan to the surface of CHO
but had no e¡ect on processing [25].
To examine the speci¢c e¡ects of glycosylation, we mutated
conserved sites for N- and O-linked glycosylation. Mutations
of the N-linked sites N556 and N662A £anking the SEA-
module inhibit dystroglycan cleavage (Fig. 5). The mutation
N662A completely abolishes dystroglycan processing into two
peptides whereas N556A reduces the levels of K-dystroglycan
(Fig. 5). Mutating the O-linked sites on L-dystroglycan did
not have any obvious a¡ect on dystroglycan processing other
than a change in molecular weight (T735A mutant). These
data show that N-linked glycosylation is a prerequisite for
e⁄cient proteolytic processing. These changes in dystroglycan
processing could be a product of misfolding caused by the
inhibition of N-linked glycosylation.
Proteins that misfold in the ER are translocated back to the
cytosol and degraded by the proteasome, a process know as
ER-associated degradation [30]. By adding the proteasome
inhibitor lactacystin to dystroglycan-transfected cells that
were pre-treated with tunicamycin, a population of uncleaved,
partially processed dystroglycan was detected (Fig. 5A), indi-
cating that misfolded dystroglycan is degraded by the protea-
some. Similar results were obtained with the N662A mutant,
again suggesting that misfolded protein was degraded by the
proteasome (Fig. 5B). However, lactacystin was also found to
inhibit the processing of wild-type dystroglycan (Fig. 5C).
Whilst lactacystin is a potent proteasome inhibitor it has
also been reported to inhibit the action of some proteases
such as cathepsin A [31] and tripeptidyl peptidase II [32]. It
is therefore possible that lactacystin inhibits the unidenti¢ed
protease that processes the dystroglycan precursor. Interest-
ingly, the proteasome inhibitor MG132 has recently been
shown to rescue surface expression of the DGC in the mdx
model of muscular dystrophy, showing that proteasome activ-
ity enhances disease progression in these mice [33].
In conclusion, we have demonstrated that glycosylation and
proteolytic processing are not essential for targeting of dys-
troglycan to the cell surface. These data are important for
understanding the mechanism of dystroglycan tra⁄cking but
are also clinically relevant because secondary alterations in
dystroglycan processing are associated with several forms of
CMD.
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